Disulfiram for Cocaine-Alcohol Abuse - 3
This study has been completed.
Sponsor:
Collaborator:
VA Connecticut Healthcare System
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000278
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: December 2002
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate disulfiram for cocaine-alcohol abuse.
| Condition | Intervention | Phase |
|---|---|---|
|
Alcohol-Related Disorders Cocaine-Related Disorders |
Drug: Disulfiram |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | Disulfiram for Cocaine-Alcohol Abuse |
Resource links provided by NLM:
Further study details as provided by National Institute on Drug Abuse (NIDA):
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Please contact site for information.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000278
Locations
| United States, Connecticut | |
| VA Connecticut Healthcare System | |
| New Haven, Connecticut, United States, 06519 | |
Sponsors and Collaborators
VA Connecticut Healthcare System
Investigators
| Principal Investigator: | Thomas R Kosten, M.D. | VA Connecticut Healthcare System |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00000278 History of Changes |
| Other Study ID Numbers: | NIDA-09250-3, P50-09250-3 |
| Study First Received: | September 20, 1999 |
| Last Updated: | August 16, 2005 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Alcoholism Alcohol-Related Disorders Cocaine-Related Disorders Substance-Related Disorders Mental Disorders Disulfiram |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Alcohol Deterrents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 21, 2013